Abstracts tagged "spondyloarthritis"

Abstract Number: 1755 • ACR Convergence 2024
Single Cell TCR Sequencing Suggests Potential Limitations of TRBV9-depleting Therapies in Axial Spondyloarthritis
Michael Paley¹, Xinbo Yang², Lynn Hassman¹, Grace Paley¹, Nicole Linskey¹, Ryan Agnew¹, Paulo Arantes de Faria¹, Annie Feng¹, Sophia Li¹, Elisha Roberson¹, Philip Ruzycki¹, Ekaterina Esaulova¹, Jennifer Laurent¹, Lacey Feigl¹, Luke Springer¹, Chang Liu¹, K. Chris Garcia³ and Wayne Yokoyama⁴, ¹Washington University in St. Louis, Saint Louis, MO, ²Sloan Kettering Institute, New York, NY, ³Stanford, Stanford, CA, ⁴Washington University School of Medicine, St Louis, MO
Background/Purpose: TRBV9 depletion is a novel strategy for the treatment of HLA-B27+ axial spondyloarthritis (axSpA) and has achieved clinical remission in at least one patient.…
Abstract Number: 2343 • ACR Convergence 2024
Temporal Trends in and Associations with NSAID Prescription in Adult and Pediatric Patients with IBD
Adam Mayer¹, Rui Xiao², Andrew Grossman³, Meenakshi Bewtra⁴, Michael George² and Pamela Weiss⁵, ¹University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia, ⁴University of Pennsylvania, Philadelphia, ⁵Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The role of nonsteroidal anti-inflammatory drugs (NSAIDs) in the management of musculoskeletal symptoms in patients with inflammatory bowel disease (IBD) and IBD-associated arthritis remains…
Abstract Number: 0395 • ACR Convergence 2024
Assessment of Enthesitis by Pediatric Rheumatology Providers
Erin Treemarcki¹, Shirley Tse², Marisa Klein-Gitelman³, Adam Mayer⁴, Hemalatha Srinivasalu⁵, Heather Walters⁶ and Melissa Oliver⁷, and the CARRA Juvenile Spondyloarthritis Workgroup and the CARRA investigators, ¹University of Utah, Salt Lake City, UT, ²SickKids, Toronto, ON, Canada, ³Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Children's National Hospital, Washington, DC, ⁶Northwell Health, New Hyde Park, NY, ⁷Indiana University, Indianapolis, IN
Background/Purpose: Enthesitis is a characteristic feature of enthesitis related arthritis (ERA) but can be found in other juvenile idiopathic arthritis (JIA) subtypes. It occurs with…
Abstract Number: 0553 • ACR Convergence 2024
Analyzing the Utilization of HLA-B27 Testing in a Large Rural Health System: Implications for Diagnostic Appropriateness
Sanjeev Shrestha¹, Angela Bobak², Idorenyin Udoeyo³, Pradeep Puri⁴, Jordan Law⁵ and David Bulbin⁶, ¹Geisinger Medical Center, Bloomsburg, PA, ²Geisinger Medical Center Internal Medicine Residency, Danville, PA, ³Geisinger Medical Center, Danville, PA, ⁴Geisinger Medical Center, Danville, ⁵Geisinger Health System, Danville, ⁶Geisinger Health System, Danville, PA
Background/Purpose: Human leukocyte antigen (HLA)-B27 is linked to spondyloarthropathies (SpA), uveitis, and inflammatory bowel disease (IBD). By analyzing ordering diagnoses and final diagnoses during patient…
Abstract Number: 0575 • ACR Convergence 2024
Combined Testing of anti-CD74 IgA and Anti-UH-axSpA Antibodies Increases the Diagnostic Potential for axSpA
Kurt de Vlam¹, Pieter Ruytinx², Elien luyten², Anouk Agten², Frank Vandenabeele² and Veerle somers², ¹Department of Rheumatology, UZ Leuven, and Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium, ²Universiteit Hasselt, Hasselt, Belgium
Background/Purpose: Diagnosis of axial spondyloarthritis (axSpA) is challenging and a specific laboratory diagnostic test is lacking. Previously, we identified novel immunoglobulin G (IgG) and IgA…
Abstract Number: 0925 • ACR Convergence 2024
Macrophages Produce Bone Anabolic Factors in Settings of Inflammation-Induced Bone Formation
Jia (Sijia) Chen¹, Megan Hanlon², Catherine Manning³, Susan MacLauchlan¹, Paul Hoover⁴, Christian Jacome-Galarza⁵ and Ellen Gravallese⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³Brigham and Women's Hospital, Dedham, MA, ⁴Brigham and Women's Hospital, SWAMPSCOTT, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: Understanding the pathogenesis of inflammation-induced pathologic bone formation remains a significant challenge in spondyloarthritis patients. We thought to uncover the pivotal events driving the…
Abstract Number: 1443 • ACR Convergence 2024
Natural Course of Degenerative Lesions of the Spine on Radiographs and MRI in Axial SpondyloarthritisFollowed 10 Years in the DESIR Cohort
Laura PINA VEGAS¹, Miranda van Lunteren², Damien Loeuille³, Caroline Morizot⁴, Esther Newsum⁵, Sofia Ramiro⁶, Floris van Gaalen⁷, Alain SARAUX⁸, Pascal Claudepierre⁹, Antoine Feydy¹⁰, Desiree van der Heijde¹¹ and Monique Reijnierse¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ³Phd, Nancy Vandoeuvre, Lorraine, France, ⁴Nancy University hospital, Nancy, France, ⁵Nij Smellinghe, Drachten, Netherlands, ⁶Leiden University Medical Center, Bunde, Netherlands, ⁷LUMC, Leiden, Zuid-Holland, Netherlands, ⁸CHU Brest, Brest, France, ⁹CHU Henri Mondor, AP-HP/EpiDermE, UPEC, Créteil, France, ¹⁰CHU Cochin, AP-HP, Paris, France, ¹¹Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands
Background/Purpose: Radiographs and MRI are the two imaging techniques often used to assess structural lesions in axial spondyloarthritis (axSpA). A high prevalence of degenerative lesions…
Abstract Number: 1756 • ACR Convergence 2024
What Is the Impact of Prior TNF Inhibitor Treatment on the Time to Achieve Low Disease Activity and the Durability of Low Disease Activity? Real-world Results Based on 17 858 European Patients with Axial Spondyloarthritis Initiating a TNF Inhibitor or an IL-17A Inhibitor
Jette Heberg¹, Stylianos Georgiadis², Marion Pons³, Anne Gitte Loft⁴, Brigitte Michelsen⁵, Louise Linde³, Daniela DiGuiseppe⁶, Simon Horskjær Rasmussen³, Mehrdad Kazemi³, Gary Macfarlane⁷, Gareth Jones⁷, Karin Laas⁸, Sigrid Vorobjov⁹, Isabel Castrejon¹⁰, Ziga Rotar¹¹, Katja Perdan-Pikmajer¹¹, Ladislav Šenolt¹², Jana Baranová¹³, Bente Glintborg¹⁴, Adrian Ciurea¹⁵, Miguel Bernardes¹⁶, Paula Valente¹⁷, Bjorn Gudbjornsson¹⁸, Gerdur Gröndal¹⁸, Gunnstein Bakland¹⁹, Catalin Codreanu²⁰, Corina Mogosan²⁰, Florenzo Iannone²¹, Roberto Caporali²², Johan Karlsson Wallman²³, Vappu Rantalaiho²⁴, Ritva Peltomaa²⁵, Karel Pavelka²⁶, Pavel Horak²⁷, Diogo Esperança Almeida²⁸, Sara Dias Rodrigues²⁹, Lykke Oernbjerg², Mikkel Ostergaard³⁰ and Merete Hetland³¹, ¹Rigshospitalet Glostrup, København V, Denmark, ²Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ³Rigshospitalet Glostrup, Glostrup, Denmark, ⁴Aarhus University Hospital and Aarhus University, Horsens, Denmark, ⁵Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, ⁶Karolinska Institutet, Stockholm, ⁷University of Aberdeen, Aberdeen, United Kingdom, ⁸East-Tallinn Central Hospital, Tallinn, Estonia, ⁹National Institute for Health Development, Tallinn, Estonia, ¹⁰Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain, ¹¹University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹³Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ¹⁴DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ¹⁵University Hospital Zurich, Zürich, Switzerland, ¹⁶São João Hospital Center and FMUP, Lisboa, Portugal, ¹⁷Rheumatology Department, Hospital de São Sebastião, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal, ¹⁸Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹⁹Department of Rheumatology, University Hospital North Norway, Tromsø, Norway, ²⁰University of Medicine and Pharmacy, Bucharest, Romania, ²¹Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ²²Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ²³Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, ²⁴Tampere University Hospital, Tampere University and Kanta-Häme Central Hospital, Tampere, Finland, ²⁵Helsinki University Hospital and University of Helsinki, Helsinki, Finland, ²⁶Institute of Rheumatology and Charles University, Praha, Czech Republic, ²⁷3rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic, ²⁸Hospital de Braga, Braga, Portugal, ²⁹Serviço de Reumatologia, Hospital Egas Moniz, Unidade Local de Saúde Lisboa Ocidental, Lisboa, Portugal, ³⁰Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ³¹Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) and Interleukin-17Ai inhibitors (IL-17Ai) have shown effectiveness in achieving low disease activity (LDA) in patients with axial spondyloarthritis (axSpA).…
Abstract Number: 2345 • ACR Convergence 2024
Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis
Andre Lucas Ribeiro¹, Virginia Carrizo Abarza², Dafna Gladman³, Vinod Chandran⁴ and Lihi Eder⁵, ¹Women's College Hospital & University of Toronto, Porto Alegre, Rio Grande do Sul, Brazil, ²Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a complex inflammatory disease where achieving remission remains challenging despite multiple approved biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs).…
Abstract Number: 0401 • ACR Convergence 2024
Biologic Abatement and Capturing Kids Outcomes and Flare Frequency in Juvenile Spondyloarthritis: Baseline Characteristics and Enrollment
Cora Sears¹, Cassandra Muir¹, Timothy Brandon¹, Polly Ferguson², Colleen Correll³, Margalit Rosenkranz⁴, Kevin Baszis⁵, Tzielan Lee⁶, Edward Oberle⁷, Matthew Stoll⁸, Kathryn Cook⁹, Eyal Muscal¹⁰, Hemalatha Srinivasalu¹¹, Daniel Lovell¹², Sampath Prahalad¹³, Michal Cidon¹⁴, Evan Mulvihill¹⁵, Marisa Klein-Gitelman¹⁶, Daniel Kingsbury¹⁷, Jennifer Cooper¹⁸, Natalie Rosenwasser¹⁹, Erin Treemarcki²⁰, Joyce Chang²¹, Stacey Tarvin²², Heather Walters²³, Michael Shishov²⁴, Lisa Buckley²⁵, Mary Toth²⁶, Ashley Cooper²⁷, Rui Xiao²⁸, Emily Neu²⁹, Melanie Kohlheim³⁰, Jenny Leal³¹, Kweli Archie³², English Holland³³, Miles Holland³⁴, Aamena Hameed³⁵, Asad Khan³⁶, Lynn Murphy³⁷, Sean Murphy³⁸, Justin Neu²⁹, Rachel Richmond³⁹, Dylan Suplee⁴⁰, Theresa Suplee⁴¹, Dawn Wiley⁴² and Pamela Weiss⁴³, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Iowa Carver College of Medicine, Iowa City, IA, ³University of Minnesota, Minneapolis, MN, ⁴UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ⁵Washington Univ in St. Louis School of Medicine, St Louis, MO, ⁶Stanford University School of Medicine, Palo Alto, CA, ⁷Nationwide Children's Hospital, Columbus, OH, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Akron Children's Hospital, Akron, OH, ¹⁰Baylor College of Medicine, Houston, TX, ¹¹Children's National Hospital, Washington, DC, ¹²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹³Emory + Children's Pediatric Institute, Atlanta, GA, ¹⁴Children's Hospital of Los Angeles, Los Angeles, CA, ¹⁵Nemours/A.I.duPont Hospital for Children, Wilmington, DE, ¹⁶Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ¹⁷Legacy Health, Portland, OR, ¹⁸University of Colorado/Children's Hospital Colorado, Aurora, CO, ¹⁹Seattle Children's Hospital, Seattle, WA, ²⁰University of Utah, Salt Lake City, UT, ²¹Boston Children's Hospital, Boston, MA, ²²Indiana University School of Medicine, Indianapolis, IN, ²³Northwell Health, New Hyde Park, NY, ²⁴Phoenix Children's Hospital, Phoenix, AZ, ²⁵Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, ²⁶Nemours Foundation, Orlando, FL, ²⁷Children's Mercy Kansas City, Kansas City, MO, ²⁸University of Pennsylvania, Philadelphia, PA, ²⁹Parent Partner, Sidney, OH, ³⁰Parent Partner, Granville, OH, ³¹Parent Partner, Columbus, OH, ³²Parent Partner, Philadelphia, PA, ³³Parent Partner, Williamsburg, VA, ³⁴Patient Partner, Williamsburg, VA, ³⁵Parent Partner, Franklin Park, NJ, ³⁶Patient Partner, Franklin Park, NJ, ³⁷Parent Partner, Haddon Heights, NJ, ³⁸Patient Partner, Haddon Heights, NJ, ³⁹Parent Partner, Albuquerque, NM, ⁴⁰Patient Partner, Maple Shade, NJ, ⁴¹Parent Partner, Maple Shade, NJ, ⁴²Parent Partner, Downingtown, PA, ⁴³Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Inactive disease is the goal for youth with spondyloarthritis (SpA). Many patients are interested in stopping medications after inactive disease is achieved. The risk…
Abstract Number: 0554 • ACR Convergence 2024
Different Prevalence of Intestinal Inflammation in Radiographic and Non-radiographic Axial Spondyloarthritis. Data from EISER Study
Carolina Merino¹, Zulema Plaza², Jordi Gratacos Masmitja³, Iago Rodríguez-Lago⁴, Elisa Trujillo⁵, Ignacio Marin-Jimenez⁶, Eva Perez Pampin⁷, Manuel Barreiro⁸, Vanesa Hernández-Hernández⁹, Marta Carrillo-Palau¹⁰, Maria Luz Garcia Vivar¹¹, Maria Carmen Muñoz¹², María Lourdes Ladehesa-Pineda¹³, Eva Iglesias Flores¹⁴, Yago González-Lama¹⁵, Marta Arevalo Salaet¹⁶, Xabier Calvet¹⁷, Ana Gutierrez-Casbas¹⁸ and JESUS SANZ SANZ¹⁹, and EISER group, ¹Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, ²Fundacion Española de Reumatología, Madrid, Spain, ³University Hospital Parc Taulí, Sabadell, Spain, ⁴Gastroenterology department. Hospital Universitario Galdakao-Usansolo, Instituto de Investigación Sanitaria Biobizkaia, Galdakao, Bizkaia, Spain, Galdakao, Spain, ⁵Rheumatology department. Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, ⁶Gastroenterology department. Hospital Universitario Gregorio Marañón, Madrid, Spain, ⁷Rheumatology department. Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Santiago de Compostela, Spain, ⁸Gastroenterology department. Hospital Clínico Universitario de Santiago de Compostela Santiago de Compostela, Spain, Santiago de Compostela, Spain, ⁹Hospital Universitario de Canarias, San Cristobal de La Laguna, Canarias, Spain, ¹⁰Gastroenterology department. Hospital Universitario Canarias, La Laguna, Spain., Santa Cruz de Tenerife, Spain, ¹¹Basurto Hospital, Bilbao, Spain, ¹²Gastroenterology department. Hospital Universitario Basurto Hospital Universitario Basurto. Bilbao. Spain., Bilbao., Spain, ¹³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ¹⁴Gastroenterology department. Hospital Reina Sofia, Córdoba, Spain, Cordoba, Spain, ¹⁵Servicio de Gastroenterología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Majadahonda, Spain, ¹⁶Parc Tauli Hospital Universitari I3PT, Rheumatology, Medicine Department, UAB, Sabadell, Spain, ¹⁷Gastroenterology department. Parc Taulí, Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí. Universitat Autònoma de Barcelona. Sabadell, Spain, Sabadell, Spain, ¹⁸Gastroenterology department. Hospital General Universitario de Dr. Balmis de Alicante. ISABIAL y CIBERehd, Alicante, Spain, Alicante, Spain, ¹⁹Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain
Background/Purpose: Axial spondyloarthritis (AxSpA) encompasses both non-radiographic axial spondyloarthritis (nr-AxSpA) and radiographic axial spondyloarthritis (r-AxSpA), also known as ankylosing spondylitis (AS). Although nr-AxSpA is often…
Abstract Number: 0576 • ACR Convergence 2024
Less Than 15% Unfavourable Pregnancy Outcomes in Patients with Recent-onset Axial Spondyloarthritis: The Analysis of the 10 Years DESIR Cohort Follow-up
Madeleine FRANC¹, Anne Tournadre² and Anna Molto³, ¹Groupe Hospitalier Cochin, APHP, Paris, France, ²Service de Rhumatologie, centre hospitalier universitaire de Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France, ³Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Only scarce data is available regarding pregnancy outcomes in early axSpA. The objective of this study was to determine (a) the factors associated with…
Abstract Number: 1010 • ACR Convergence 2024
Total Cost Risk Scores and Barrier Categories in Patients with Axial Spondyloarthritis and Associated Factors
Marina Magrey¹, Yashashvi Raghuwanshi², Tyler Barnett², lindsay Frumker³ and Omer Pamuk⁴, ¹Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, ²University hospitals, Cleveland, OH, ³University Hospitals Cleveland, cleveland, OH, ⁴University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Axial spondyloarthritis (axSpA) is associated with an increased risk of morbidity and mortality. Patients with axSpA suffer from chronic back pain, and epidemiological studies…
Abstract Number: 1444 • ACR Convergence 2024
Characterization and Comparison of MRI Findings in Axial Spondyloarthritis, Axial Psoriatic and Chronic Non-inflammatory Back Pain
Mauricio Parada¹, maría Luisa Molina¹, Daniel Ríos¹, Daniela Suarez¹, Natalie Hitchin², Cristóbal Bravo², Nicolás Guzmán² and Annelise Goecke¹, ¹Hospital Clínico Universidad de Chile, santiago, Chile, ²Universidad de Chile, Santiago, Chile
Background/Purpose: MRI of the sacroiliac joints (SIJ) is part of the evaluation of patients with suspected axial spondyloarthritis (axSpA). However, sacroiliitis (SI) could be a…
Abstract Number: 1757 • ACR Convergence 2024
Bimekizumab Treatment Resulted in Improvements in MRI Inflammatory and Structural Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis: 52-Week Results and Post Hoc Analyses from Two Phase 3 Studies
Walter Maksymowych¹, Sofia Ramiro², Denis Poddubnyy³, Xenofon Baraliakos⁴, Robert Lambert¹, Ute Massow⁵, Thomas Vaux⁶, Chetan Prajapati⁶, Alexander Marten⁵, Natasha de Peyrecave⁷ and Mikkel Ostergaard⁸, ¹University of Alberta, Edmonton, AB, Canada, ²Leiden University Medical Center, Bunde, Netherlands, ³Charite-Universitatsmedizin Berlin, Berlin, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Brussels, Belgium, ⁸Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark
Background/Purpose: The impact of bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL-17A, on structural lesions in patients (pts)…

« Previous Page
1
…
6
7
8
9
10
…
41
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].